A retroviral late-domain promotes cell-surface expression, extracellular vesicle formation, and immunogenicity of a trimeric HIV-1 Env antigen

Vaccines work by teaching the immune system to recognize a specific threat, often by presenting a harmless piece of a virus. For many years, scientists have tried to improve how well these pieces are seen by the body's defenses. A major breakthrough in recent years has been the use of messenger RNA, or mRNA, which acts as a set of instructions to tell human cells to build a viral protein themselves. When the cell builds this protein, it often anchors it to its outer surface, much like a flag planted on a wall. This membrane-anchored state is powerful because it mimics the natural shape of the virus more closely than a loose protein floating in a solution, making it easier for the immune system to learn how to fight the real thing. However, getting these anchored proteins to stay on the surface long enough to be noticed, or to be released in a way that triggers a strong defense, remains a challenge. Researchers are constantly searching for small genetic switches that can keep these viral flags visible and effective.

In a study published in October 2026, a team of scientists at Boston Children's Hospital and the Broad Institute explored a new way to make these viral flags more visible and potent. They focused on the HIV-1 virus, specifically a stabilized version of its outer shell protein, known as the Env trimer. The researchers wanted to see if they could attach a tiny, specific sequence of genetic code to the tail end of this protein to improve how the immune system responds to it. They tested several different sequences, including ones known to help viruses escape from cells and others designed to prevent the cell from swallowing the protein back up. The goal was to find a combination that would keep the protein on the cell surface, encourage the release of tiny bubbles called extracellular vesicles that carry the protein away, and ultimately train the immune system to produce strong, protective antibodies.

The team created nine different versions of the HIV-1 protein, each with a different genetic tail attached. They introduced these instructions into human cells grown in a lab dish to see how well the proteins appeared on the cell surface. They used special antibodies that act like flashlights to highlight the proteins. They found that two specific additions worked well: a sequence called EPM, which stops the cell from pulling the protein inside, and a sequence called FIV p2, which comes from the feline immunodeficiency virus. Both of these additions helped the HIV-1 protein stay on the cell surface better than the standard version. However, a third sequence, known as EABR, which was previously successful with other viruses, actually made the HIV-1 protein disappear from the surface more quickly, even when combined with the EPM sequence. This suggested that what works for one virus does not always work for another, and that the HIV-1 protein has unique needs.

To see which version would make the best vaccine, the researchers moved to experiments with mice. They injected the mice with mRNA instructions for the different protein versions and measured the antibodies the mice produced. The results were clear: the mice that received the instructions for the version with the FIV p2 tail produced significantly higher levels of antibodies than those that received any other version, including the standard protein or the ones with the EPM or EABR tails. This effect was seen early on, just after the first injection, and it persisted through subsequent shots. The FIV p2 version was particularly good at triggering antibodies that could neutralize the virus, meaning they could stop it from infecting cells. In contrast, the version with the EABR tail, which had been successful in previous studies with different viruses, failed to generate a strong response in this context.

The researchers also looked at what was happening inside the cells to understand why the FIV p2 version worked so well. They found that cells carrying the FIV p2 instructions held onto more of the protein overall and displayed more of it on their surface. At the same time, these cells released more of the tiny extracellular vesicles that carry the protein away. These vesicles are important because they can travel through the body and present the viral protein to immune cells in a way that boosts the response. The FIV p2 tail seemed to strike a perfect balance: it kept enough protein on the cell surface to be seen immediately, while also releasing enough vesicles to spread the signal. Other versions either disappeared too quickly or failed to release enough vesicles. The team also tested whether this FIV p2 tail worked on other types of proteins, such as those from the flu virus or the Epstein-Barr virus, and found that it improved their surface expression as well, suggesting this small genetic switch might be useful for many different vaccines.

One of the most interesting findings concerned how the immune system reacted over time. In some experiments, the researchers used mice that had been engineered to have a specific type of immune cell designed to target a difficult-to-reach part of the HIV-1 virus. They found that the FIV p2 version triggered a very fast and strong response from these cells, leading to high levels of neutralizing antibodies early on. However, this rapid response seemed to limit the long-term refinement of the immune memory in some specific ways, as the immune system focused on the immediate threat. In contrast, the version with the EABR tail, which produced fewer antibodies overall, allowed for a different kind of immune activity that kept certain immune cells in a training zone for longer. Despite this nuance, the overall conclusion was that the FIV p2 tail generated the strongest and most effective antibody response against the HIV-1 protein.

The study highlights that the success of a vaccine often depends on the tiny details of how the viral protein is presented to the body. The FIV p2 sequence, which is only 18 amino acids long, proved to be a powerful tool for enhancing the visibility and effectiveness of the HIV-1 protein. Unlike other sequences that were either too aggressive in releasing the protein or not effective enough at keeping it on the surface, FIV p2 provided a steady, high-level display that the immune system could easily recognize and attack. This discovery offers a new path for designing better vaccines, not just for HIV, but potentially for other viruses where getting the immune system to see the right shape of the protein is the key to success. The work suggests that by carefully choosing these small genetic additions, scientists can fine-tune how vaccines interact with the body, potentially leading to more effective protection with fewer doses.